Mainz Biomed B.V. (MYNZ) has released an update.
Mainz Biomed has announced a collaboration with Thermo Fisher Scientific to develop a next-generation colorectal cancer screening test. This partnership aims to leverage Thermo Fisher’s advanced technologies to enhance Mainz Biomed’s mRNA-based screening tests, which have shown significant clinical success in detecting early-stage cancer and precancerous lesions. The collaboration is set to accelerate the availability of innovative cancer screening solutions globally.
For further insights into MYNZ stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for Flux Power Holdings, Inc. (NASDAQ:FLUX)
- ValueAct’s $1B Stake in Meta Platforms is a Constructive Bet, Not an Activist Move
- Spirit Airlines Plunges 63% on Possibility of Bankruptcy Deal Wiping Out Shareholders’ Wealth
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
